相关实验视频

Updated: Mar 17, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

UMG1定义了一个可向的T细胞淋巴瘤子集,并通过一流的CD3ε双特异性参与者实现精密免疫疗法

Daniele Caracciolo¹, Carlo Gentile¹, Sara Squillacioti¹

¹Department of Experimental and Clinical Medicine (DMSC), Magna Graecia University, Catanzaro, Italy.

Hematological oncology

|March 16, 2026

概括

一种新的双特异性T细胞激活剂 (UMG1/CD3ε-BTCE) 对表达UMG1标的T细胞淋巴瘤 (TCL) 显示出强烈的活性. 这种免疫治疗方法选择性地向癌细胞,为侵略性的血液恶性瘤提供了希望.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
血液学血液学血液学

背景情况:

T细胞淋巴瘤 (TCLs) 是一种具有攻击性的血液性恶性瘤,通常对传统疗法有抗性.
UMG1是一种独特的CD43表位,在T细胞恶性瘤上表达,但在正常组织中基本上不存在.
以前的研究表明,UMG1/CD3ε-BTCE对T细胞急性淋巴细胞白血病和扩散性大B细胞淋巴瘤的疗效.

研究的目的:

研究UMG1/CD3ε-BTCE在体外对各种类型的T细胞淋巴瘤的疗效.
评估TCL患者样本和细胞系中的UMG1表达水平.
评估UMG1/CD3ε-BTCE作为TCLs的精密免疫疗法的潜力.

主要方法:

组织微阵列 (TMAs) 的免疫组织化学 (IHC) 分析用于TCL样本中的UMG1表达.
流细胞计检测TCL细胞系上的UMG1表达.
在体外评估UMG1/CD3ε-BTCE介导的针对UMG1-表达TCL细胞的重定向细胞毒性.
对UMG1/CD3ε-BTCE与HDAC抑制剂SAHA的协同作用的评估.

主要成果:

在62.3%的TCL样本中发现了高UMG1表达,包括PTCL-NOS和ALK阴性ALCL.
所有T细胞前淋巴细胞白血病 (T-PLL) 标本 (27/27) 和大多数TCL细胞系表达UMG1.1.
诱导UMG1/CD3ε-BTCE强大的,剂量依赖的T细胞介导的细胞毒性和炎症性细胞因子释放对UMG1表达的TCL细胞.
通过与SAHA联合治疗,UMG1/CD3ε-BTCE的疗效得到了增强.

结论:

UMG1/CD3ε-BTCE显示出对T细胞淋巴瘤的显著子集具有选择性和强大的抗瘤活性.
UMG1表达是一种可行的生物标志物,用于识别可能受益于UMG1/CD3ε-BTCE治疗的TCL患者.
这些发现支持UMG1/CD3ε-BTCE的发展,作为UMG1表达的侵略性血液恶性瘤的精密免疫疗法.

关键词:

在T-PLL中.在T细胞淋巴瘤.UMG1 UMG1 UMG1 UMG1 UMG1 UMG1 UMG1 UMG1 UMG1 UMG1 UMG1 UMG1 UMG1 两种特异性T细胞参与者.癌症癌症癌症癌症癌症免疫疗法免疫疗法淋巴瘤淋巴瘤是什么

更多相关视频

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...